13 November, 2023

Farmaindustria’s protection of personal data in research is already a benchmark in Europe and is a further incentive to attract clinical trials to Spain.

The Code of Conduct regulating the processing of personal data in clinical trials approved in 2022 makes it easier for companies and researchers to correctly comply […]
2 November, 2023

Medicines for rare diseases already account for 39% of those authorised in Europe, but take more than two years to reach Spain

The director of Farmaindustria’s Access Department, Isabel Pineros, participates in the XVI International Congress on Rare Diseases: “In recent years we have seen great advances in […]
30 October, 2023

New drugs reduce cancer deaths in Spain by almost 30%.

This is demonstrated by a recent study by Professor Frank R. Lichtenberg of Columbia University, which has just been published in the journal Value in Health. […]
24 October, 2023

Precision medicine opens new hopes in breast cancer: 14 targeted therapies authorized since 2018

On World Disease Day, which is celebrated on October 19, Farmaindustria remembers the importance of clinical trials, the previous step for the arrival of innovative treatments […]
17 October, 2023

Farmaindustria launches a proposal to speed up the delivery of innovative medicines to patients in cases where the benefit is most relevant

The document proposes, without the need for a regulatory change, a procedure that would allow the equitable arrival of drugs that meet certain criteria that make […]
11 October, 2023

Urgent measures are needed to encourage innovation and production and enable Europe to make up lost ground.   In a political context with elections called for the European Parliament at the beginning of June 2024 and with Spain holding the presidency of […]
9 October, 2023

Paediatric clinical research advances in Spain driven by collaboration between researchers, healthcare professionals and the pharmaceutical industry

Between 2020 and 2022, 446 clinical trials with children and adolescents were conducted in our country, almost half of them focused on rare diseases and 90.4% […]
4 October, 2023

“Artificial intelligence and technology are driving digital therapies, which benefit not only patients, but the healthcare system and society as a whole”.

In recent years, the number of applications capable of interacting with patients to prevent, manage or treat diseases has increased, and which can also generate data […]
2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research

The 7th Congress of Patients’ Organisations, organised by the POP, analyses the application of the new European Regulation on Clinical Trials. Farmaindustria’s director general, Juan Yermo, […]
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society

The vast majority of them are aimed at modifying the course of the disease, according to an Iqvia report on the future of R&D. In Spain […]
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care

Only 7.5% are carried out in health centres. In order to alleviate this situation, Farmaindustria has presented a programme to promote them in outpatient clinics. Source: […]
14 September, 2023

Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros

“We are going to create a favourable environment”. This statement by José Manuel Miñones is the first step towards a roadmap that would highlight the key […]
12 September, 2023

Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

“We must take advantage of the opportunity provided by the Spanish Presidency of the Council of the EU to include health, medicines and the innovative pharmaceutical […]
25 July, 2023

The rise of combination therapies in cancer opens up an opportunity for patients, but requires improved access procedures

Over the next five years, the number of cancer treatments consisting of more than one drug will double, with 68 authorisations expected to be granted The […]
18 July, 2023

The 22nd Meeting of the Spanish Pharmaceutical Industry will focus on the reform of European legislation and its impact on Spain

The forum, organised by the Menéndez Pelayo International University (UIMP) and Farmaindustria, will be held on 7 and 8 September in Santander Patient representatives, drug authorities, […]
10 July, 2023

The pharmaceutical industry, one of the most value-added sectors in Europe

The sector invests 41.5 billion euros in research and directly employs some 840,000 people 300 billion, exports ¤565 billion and contributes ¤175 billion to the EU-27 […]
4 July, 2023

Pharmaceutical companies set a record for investment in collaborations with the healthcare system through R&D and support for lifelong learning

Last year, the sector contributed 313 million euros for organisations and healthcare professionals to participate in research and development activities for new treatments For the eighth […]
27 June, 2023

Spain, a global power in clinical trials

One out of every three tests carried out in Europe takes place in Spain. Investment has grown by 5.3% annually since 2011, to almost 800 million […]
19 June, 2023

“We must bring clinical trials closer to the patient’s home, and for this, research in primary care is vital”

The associate director of Clinical and Translational Research at Farmaindustria, Amelia Martín Uranga, explained at a forum organised by the POP that work is already underway […]
5 June, 2023

“Difficulties in access to orphan drugs in Spain are detrimental to patients, the healthcare system and pharmaceutical companies”

The director of Farmaindustria’s Access Department, Isabel Pineros, explains the situation of these drugs in Spain at a conference organised by the Kronos Foundation, the Hospital […]
30 May, 2023


On 23 May, part of the Distefar team attended the biomedical research technology platform. The opening was a conference by Juan José Vaquero, entitled “Strategy for […]
25 May, 2023

“The availability of oncology drugs needs to improve, as only 57% of those approved in Europe are available”

The director of Farmaindustria’s Access department analyses the challenges in the access of these patients to pharmaceutical innovation at a conference of the Spanish Society of […]
22 May, 2023

Clinical trials, hope for today’s patients and new medicines for tomorrow’s patients

International Clinical Trials Day commemorates the importance of clinical trials every 20 May Clinical trials advance medicine and address unmet medical needs Source: In the […]
11 May, 2023

“The increase in international competitiveness and digitalisation will require more investment to ensure that Spain remains at the forefront of biomedical R&D”

The Deputy Director General of Farmaindustria, Javier Urzay, recalls that this is a key moment to define the country’s strategy in research to face the new […]
8 May, 2023

“Bringing clinical trials closer to the patient’s home is a challenge in which the public and private sectors must go hand in hand”

This measure allows for greater participation and the inclusion of a more diverse population, which improves the scientific quality of the studies, as highlighted by Farmaindustria’s […]
2 May, 2023

Farmaindustria assures that the revision of the European pharmaceutical legislation “puts the future of the industry at risk”

In the opinion of the employers’ association, it “represents yet another barrier to patient access to innovative treatments” Source: Following the proposed revision of the […]
24 April, 2023

“It’s time for Europe to make up for lost ground in pharmaceutical innovation”

Farmaindustria brings together in Spain the main European National Associations representing the innovative pharmaceutical industry and the European Federation of the Pharmaceutical Industry together with the […]
17 April, 2023

Fifteen organisations sign up to the Code on Data Protection in Clinical Trials in its first year

Farmaindustria states that it is “the first sectoral code approved by the AEPD and a reference at European level” Source: Farmaindustria has announced that a […]
13 March, 2023

Spain authorised more than 900 clinical trials with medicines in 2022, according to the Spanish Clinical Trials Register (REEC). These figures exceed those recorded in the years prior to the pandemic

Source: Multiple sclerosis is an autoimmune disease of the central nervous system that affects the brain and spinal cord. It is caused by damage to […]
8 March, 2023

Paediatric clinical trials to grow by 24% by 2022, with special focus on cancer and nervous system diseases

Data from the Spanish Clinical Trials Register reveal the commitment of the pharmaceutical industry, which finances 88% of trials with paediatric patients. Incentives for innovation are […]
19 March, 2024

The health sector, essential for the well-being of the population and an economic engine for society The ecosystem of the private healthcare sector transcends the field of healthcare and has an impact on society and on the productive sectors of the […]
7 March, 2024

Spain takes, on average, two years to approve a drug for a minority disease

There are 146 orphan drugs approved by the European Medicines Agency. Spain has only 81 in its catalogue. It has rejected funding for 25 and is […]
5 March, 2024

22% of clinical trials underway in Spain seek new treatments for rare diseases

Research into new drugs for rare diseases has multiplied in recent years. In Spain, industry drives 90% of clinical trials for this type of disease. One […]
13 February, 2024

The Andalusian Regional Government and Farmaindustria will promote R&D&I in health with a special focus on the promotion of clinical trials.

In a press release, the Andalusian Regional Government highlights the joint commitment of both entities to continue advancing in the promotion of R&D&I, following the meeting […]
8 February, 2024

Spain is the country with the highest participation in clinical trials of new drugs in Europe

Of the 1,944 clinical trials authorised in the European Union through the new European Information System, Spanish centres participated in 845, or 43% of the total. […]
6 February, 2024

Europe calls latest cancer drugs “significant progress” for health

The European Medicines Agency has thus identified nine oncology approvals for 2023. The arrival of new treatments is directly linked to the pharmaceutical industry’s commitment to […]
2 February, 2024

The Innovative Medicines Platform sets its roadmap for 2024 with the aim of turning Spain into a major biomedical innovation hub

The Technological Platform for Innovative Medicines – whose Coordination Committee is made up of 10 representatives from the pharmaceutical industry and 10 representatives from public research […]
1 February, 2024

A common catalogue of biomarkers in the National Health System is a great step forward for patients because it improves access to personalised medicine.

Farmaindustria welcomes the presentation by the Ministry of Health of the harmonised catalogue of genetic tests for the whole country. For this catalogue to become a […]
30 January, 2024

Frank R. Lichtenberg, Professor at Columbia University: “Life expectancy of cancer patients in Spain has increased by almost three years in the last decade thanks to the use of innovative drugs”.

The US expert unpacked the data from his study on the relationship between pharmaceutical innovation and cancer mortality in Spain between 1999 and 2016 in a […]
15 January, 2024

FDA approves 55 new drugs in 2023, one of the highest numbers in a decade

Infectious diseases, neurological diseases, type 2 diabetes in children, oncology and cardiac disorders are just some of the areas that benefited from the innovation drive last […]
11 January, 2024

The Distefar team is environmentally conscious and switches from buying single-use plastic bottles to glass bottles.

8 January, 2024

The pharmaceutical industry, a strategic sector for Spain and Europe

“We are the industrial area that invests the most in R&D, a productive and exporting engine”. Developing and producing new medicines for society is both […]